Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (6.999.998 €): Integration von Nano- und Biotechnologie für Beta-Zell- und Islet-Transplantation Hor01.10.2017 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Integration von Nano- und Biotechnologie für Beta-Zell- und Islet-Transplantation
The iNanoBIT project is aimed to apply nanotechnologies for imaging porcine pancreatic islet cellular transplants and induced pluripotent stem cell-derived beta-cells and subsequent regenerative processes in vivo in a porcine model. The project will develop1) novel highly sensitive nanotechnology-based imaging approaches allowing for monitoring of survival, engraftment, proliferation, function and whole body distribution of the cellular transplants in a preclinical porcine model with excellent translational potential to humans; 2) develop and validate the application of state-of-the-art imaging technologies facilitating the provision of new regenerative therapies to preclinical large animal models and patients; 3) directly contribute to the opening of a new market sector for i) imaging equipment (SPECT, PET/MR, optoacoustic imaging in preclinical large animal models and patients), ii) nano-imaging molecule supplies (nanomolecules allowing multimodality imaging of specific cell types with high sensitivity), iii) validated transplantable in vitro differentiated human beta-cells and porcinexenotransplant islets thus will reinforce the European healthcare supply chain for regenerative medicinal products. The iNanoBIT project will provide the currently missing toolbox for preclinical/clinical testing for a safe translation of regenerative medicinal cellular and tissue products, currently under preclinical and clinical trials, which is vital for the competitiveness of the European healthcare sector in this fast-growing area. The consortium of 5 SME and 3 Academic partners is coordinated and driven by the industrial partners from the field of nanotechnology, imaging and stem cell technologies, providing a perfect match and unique combination addressing the scope and expected impact of the call and providing TRL 3/4 starting points for the key technological elements, and expect to arrive to TRL6 levels of validated technologies ready for marketing by the end of the project.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| BBS NANOTECHNOLOGIA KUTATASI ES FEJLESZTESI kft. | 710.726 € |
| BIOTALENTUM TUDASFEJLESZTO kft. | 1.301.341 € |
| Defymed | 645.625 € |
| ITHERA MEDICAL GmbH | 636.041 € |
| ITHERA SCIENTIFIC GmbH | 0,00 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 1.629.575 € |
| Mediso Orvosi Berendezes Fejleszto es Szerviz kft. | 795.375 € |
| Universita' Degli Studi Di Milano-Bicocca | 652.564 € |
| Universite Catholique de Louvain | 628.750 € |
Quelle: https://cordis.europa.eu/project/id/760986
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
